Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

Pyrintegrin [1228445-38-2]

Imprimer

Référence T16695-5mg

Conditionnement : 5mg

Marque : TargetMol

Demander plus d'informations

Pyrintegrin

Copy Product Info

Pyrintegrin, a β1-integrin agonist, promotes the survival of embryonic stem cells, can be used as a podocyte-protective agent, and enhances cell-extracellular matrix adhesion-mediated integrin signaling.

Cas No. 1228445-38-2

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Batch Information

Select Batch

Purity:99.19%

Appearance:Solid

Color:White

Resource Download

COA HPLC HNMR LCMS

Product Introduction

Bioactivity

Description	Pyrintegrin, a β1-integrin agonist, promotes the survival of embryonic stem cells, can be used as a podocyte-protective agent, and enhances cell-extracellular matrix adhesion-mediated integrin signaling.
In vitro	Pyrintegrin decreases Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation. Pyrintegrin treatment prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells. Pyrintegrin stimulates human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol, and total triglycerides. Pyrintegrin (0-10 μM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC50 of 1.14 μM) [1][2].
In vivo	Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. Pyrintegrin decreases peak proteinuria caused by puromycin aminonucleoside-induced nephropathy. Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation. Pyrintegrin (10 mg/kg; intraperitoneal injection; once; C57BL/6J mice) treatment protects mice from LPS-induced podocyte foot process effacement and proteinuria. LPS administration decreases the levels of active β1 integrin in the podocytes, which is prevented by cotreatment with Pyrintegrin [1][2].

Chemical Properties

Molecular Weight	451.54
Formula	C₂₃H₂₅N₅O₃S
Cas No.	1228445-38-2
Smiles	Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1
Relative Density.	1.401 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 150 mg/mL (332.2 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: < 10 mg/mL (22.15 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.

10% DMSO+90% Saline: < 10 mg/mL (22.15 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.

10% DMSO+90% (20% SBE-β-CD in Saline): < 10 mg/mL (22.15 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2146 mL	11.0732 mL	22.1464 mL	110.7322 mL
5 mM	0.4429 mL	2.2146 mL	4.4293 mL	22.1464 mL
10 mM	0.2215 mL	1.1073 mL	2.2146 mL	11.0732 mL
20 mM	0.1107 mL	0.5537 mL	1.1073 mL	5.5366 mL
50 mM	0.0443 mL	0.2215 mL	0.4429 mL	2.2146 mL
100 mM	0.0221 mL	0.1107 mL	0.2215 mL	1.1073 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.